Expression of the GLI family genes is associated with tumor progression in advanced lung adenocarcinoma

World Journal of Surgical Oncology

Hiroshi Date¹  Kei Shikuma¹  Terumasa Sowa¹  Naoto Imamura¹  Makoto Sonobe¹  Masashi Ishikawa¹ 

[1] Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan

关键词: Prognosis;    Expression;    Advanced stage;    Lung adenocarcinoma;    Hedgehog signaling;    GLI;   

Others  :  1148380
DOI  :  10.1186/1477-7819-12-253

 received in 2013-08-13, accepted in 2014-07-20,  发布年份 2014

【 摘 要 】

Background

The hedgehog (Hh) signaling pathway is aberrantly activated in various cancers. Expression of the GLI family of genes, which encode for transcriptional factors of the Hh pathway, has not been fully assessed in clinical samples of advanced lung adenocarcinoma. In this study, we retrospectively evaluated the expression of the GLI family of genes in advanced stage lung adenocarcinoma samples and determined their relation to patient survival.

Methods

The levels of GLI1, GLI2, and GLI3 mRNA expression were measured by quantitative real-time polymerase chain reaction in surgically obtained tissue samples from stage II-IV lung adenocarcinoma patients (n = 102). Pairwise comparisons between all three GLI mRNA expression were performed, and after dichotomizing the patients into low and high expression groups according to each GLI mRNA expression level, survival curves were calculated and multivariate analyses were conducted.

Results

Significant positive correlation was found between GLI1 and GLI3 mRNA expression (P <0.001). Tumors with higher expression (upper 15%) of GLI1 or GLI3 mRNA were associated with poor survival in stage II-IV (5-year overall survival rates: GLI1 mRNA low, 41.7% vs. high, 20.0%, P = 0.0074; GLI3 mRNA low, 43.1% vs. high, 13.3%, P = 0.0062) and stage III-IV (5-year overall survival rates: GLI1 mRNA low, 34.0% vs. high, 0%, P = 0.0012; GLI3 mRNA low, 33.4% vs. high, 7.7%, P = 0.057) lung adenocarcinoma patients. GLI2 mRNA expression did not appear to have great clinical significance. Multivariate analysis revealed higher GLI1 mRNA expression as an independent factor for unfavorable patient survival (P = 0.0030, hazard ratio = 3.1, 95% confidence interval = 1.5-6.2), as well as tumor differentiation and stage.

Conclusions

Expression of GLI1 and GLI3 mRNA was strongly correlated, and their overexpression, especially that of GLI1, was found to be predictive of aggressive tumor behavior. This study indicates that the Hh pathway may be a key oncogenic signaling network in tumor pathogenesis and, thus, a potential therapeutic target in advanced lung adenocarcinoma.

【 授权许可】

   
2014 Ishikawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003, 123(1 Suppl):21S-49S.
• [3]William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES: Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136:701-709.
• [4]Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
• [5]Ruiz I, Altaba A, Sanchez P, Dahmane N: Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002, 2:361-372.
• [6]Ingham PW, McMahon AP: Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001, 15:3059-3087.
• [7]Matise MP, Joyner AL: Gli genes in development and cancer. Oncogene 1999, 18:7852-7859.
• [8]Kasper M, Regl G, Frischauf AM, Aberger F: GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 2006, 42:437-445.
• [9]Yang L, Xie G, Fan Q, Xie J: Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010, 29:469-481.
• [10]Teglund S, Toftgard R: Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010, 1805:181-208.
• [11]Watkins DN, Berman DM, Baylin SB: Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003, 2:196-198.
• [12]Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD, Sage J: A crucial requirement for hedgehog signaling in small cell lung cancer. Nat Med 2011, 17:1504-1508.
• [13]Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tumer Z, Tommerup N, Poulsen HS, Larsen LA: Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 2006, 52:281-290.
• [14]Sobin L, Gospodarowicz M, Wittekind C: TNM Classification of Malignant Tumours (UICC International Union Against Cancer). 7th edition. Oxford: Wiley-Blackwell Co.; 2009.
• [15]Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: Pathology & Genetics of Tumours of the Lung, Pleura, Thymus and Heart (World Health Organization Classification of Tumours), Volume 10. Lyon: IARC Press; 2004.
• [16]Velcheti V, Govindan R: Hedgehog signaling pathway and lung cancer. J Thorac Oncol 2007, 2:7-10.
• [17]Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ: Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 2007, 26:1046-1055.
• [18]Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, Lam WL, Dmitrovsky E, Capobianco AJ, Robbins DJ: The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene 2013, 32:2335-2345.
• [19]Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, Lorenzo CD, Edwards VD, Sridhar S, Hostetter G, Weiss GJ: Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer 2012, 76:191-196.
• [20]Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H: Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer 2009, 66:64-74.
• [21]Wang B, Fallon JF, Beachy PA: Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell 2000, 100:423-434.
• [22]Iwasaki H, Nakano K, Shinkai K, Kunisawa Y, Hirahashi M, Oda Y, Onishi H, Katano M: Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via upregulation of adherence-related genes. Cancer Sci 2013, 104:328-336.
• [23]Kang HN, Oh SC, Kim JS, Yoo YA: Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53. Exp Cell Res 2012, 318:539-549.
• [24]Im S, Choi HJ, Yoo C, Jung JH, Jeon YW, Suh YJ, Kang CS: Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival. Korean J Pathol 2013, 47:116-123.
• [25]Gupta S, Takebe N, Lorusso P: Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol 2010, 2:237-250.
• [26]Geissler K, Zach O: Pathways involved in drosophila and human cancer development: the notch, hedgehog, wingless, runt, and trithorax pathway. Ann Hematol 2012, 91:645-669.
• [27]Bertrand FE, Angus CW, Partis WJ, Sigounas G: Developmental pathways in colon cancer: crosstalk between WNT, BMP, hedgehog and notch. Cell Cycle 2012, 11:4344-4351.
• [28]Santoni M, Burattini L, Nabissi M, Morelli MB, Berardi R, Santoni G, Cascinu S: Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci 2013, 14:133-140.
• [29]ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, Knuchel R, Dahl E: Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer 2009, 9:298.
• [30]Mori Y, Okumura T, Tsunoda S, Sakai Y, Shimada Y: Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. Oncology 2006, 70:378-389.
• [31]Ding YL, Zhou Y, Xiang L, Ji ZP, Luo ZH: Expression of glioma-associated oncogene homolog 1 is associated with invasion and postoperative liver metastasis in colon cancer. International journal of medical sciences 2012, 9:334-338.
• [32]He HC, Chen JH, Chen XB, Qin GQ, Cai C, Liang YX, Han ZD, Dai QS, Chen YR, Zeng GH, Zhu JG, Jiang FN, Zhong WD: Expression of hedgehog pathway components is associated with bladder cancer progression and clinical outcome. Pathol Oncol Res 2012, 18:349-355.
• [33]Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez De Medina S, Moutereau S, Maille P, Soyeux P, Abbou C, Salomon L, Vacherot F, de la Taille A, Loric S, Allory Y: Comparative expression of hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 2008, 216:460-470.
• [34]Henkin RI: Vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 367:970. Author reply 970-971
• [35]Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA: A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013, 19:258-267.
• [36]Neal JW, Sequist LV: Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options in Oncol 2010, 11:36-44.